Trial Profile
A Phase 2, Open-label, Single Arm, Exploratory, Observational Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2020
Price :
$35
*
At a glance
- Drugs Fezagepras (Primary) ; Nintedanib; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Liminal BioSciences; ProMetic Biosciences
- 22 May 2019 According to a ProMetic Life Sciences media release, data from a post-hoc analysis of this trial were presented at the American Thoracic Society (ATS) 2019 International Conference.
- 12 Dec 2018 Results assessing safety, efficacy and pharmacokinetics published in the European Respiratory Journal.
- 23 May 2018 Results assessing the effect of PBI-4050 alone or in combination with pirfenidone or nintedanib on blood biomarkers linked to the fibrotic process presented at the 114th International Conference of the American Thoracic Society.